#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Trimetazidine in the treatment of angina pectoris and other forms of IHD


Authors: V. Chaloupka
Published in: Kardiol Rev Int Med 2005, 7(1): 17-20

Overview

Trimetazidine, piperazine derivative, is practically the only drug from the group of metabolic modulators used in the clinical practice

in the angina pectoris treatment. The principle of the effect of trimetazidine is selective inhibition of enzyme of beta oxidation of fatty acids in mitochondria, 3-ketoacyl-CoA-thiolase (3-KAT). The result is partial inhibition of fatty acids oxidation and stimulation of glucose oxidation. Trimetazidine has demonstrable antianginose effects in monotherapy and in the combined treatment. Former papers have already shown that TMZ has efficacy comparable with classic haemodynamic drugs. Trimetazidine is indicated mainly in the prophylaxis of angina pectoris. However, cytoprotective effects assert in other forms of ischaemic heart disease too and they are not necessarily bound on the occurrence of angina pectoris. Trimetazidine is excellently tolerated and therefore it is suitable in elderly patients, diabetics and polymorbid patients.

Keywords:
trimetazidine – angina pectoris – ischaemic heart disease – metabolic treatment


Sources

1. Bultas J. Léč­ba angi­ny pecto­ris. Jak dnes, jak zít­ra? Me­di­cí­na po pro­mo­ci 2004; 5: 14–30.

2. Packer M. Drug The­ra­py: Combi­ned be­ta–adre­nergic and calcium–entry blocka­de in angi­na pecto­ris. N Engl J Med 1989; 320: 709–718.

3. Sa­vo­nitto S, Ardissi­no D, Egstrup K et al. Combi­na­tion the­ra­py with me­topro­lol and ni­fe­de­pi­ne ver­sus mo­nothe­ra­py in pa­tients with stable angi­na pecto­ris. In­ter­na­tio­nal Multi­center Angi­na (IMA­GE) Stu­dy. J Am Coll Cardiol 1996; 27: 311–316.

4. Hra­dec M, Cha­loup­ka V, Sa­cho­vá M. Angi­na treatment Patterns Survey: Sou­čas­ný stav diagnosti­ky a léč­by ne­moc­ných se sta­bil­ní angi­nou pecto­ris v Čes­ké re­pub­li­ce. Cor Va­sa 2003; 45: 173–180.

5. Lo­paschuk GD. Pharma­co­lo­gic ra­tio­na­le for tri­me­ta­zi­di­ne in the treatment of ische­mic heart di­sea­se. Am J Cardio­vasc Drugs 2003; 3(Suppl I): 21–26.

6. Marzilli M. Cardiopro­tecti­ve effects of tri­me­ta­zi­di­ne: a re­view. Curr Med Res Opin 2003; 19: 661–672.

7. Hra­dec J. Lé­ko­vé pro­fi­ly. Tri­me­ta­zi­di­num. 2003; 13: 8–75.

8. Kan­tor P, Lu­cien A, Ko­zak R, Lo­paschuk G. The antiangi­nal drug tri­me­ta­zi­di­ne shifts cardiac energy me­ta­bo­lism from fatty acid oxi­da­tion to glu­co­se oxi­da­tion by inhi­bi­ting mi­to­chondrial long–chain 3–ke­toa­cyl coenzy­me A thio­la­se. Circ Res 2000; 86: 580–588.

9. Marzilli M, Klein WW. Effi­ca­cy and to­le­ra­bi­li­ty of tri­me­ta­zi­di­ne in stable angi­na: a me­ta–ana­ly­sis of rando­mi­zed, double–blind, controlled trials. Cor Art Dis 2003; 14: 171–179.

10. Detry JM, Sellier P, Penna­forte S et al. Tri­me­ta­zi­di­ne: a new concept in the treatment of angi­na. Compa­ri­son with propra­no­lol in pa­tients with stable angi­na. Tri­me­ta­zi­di­ne Euro­pean Multi­center Stu­dy (TEMS) Group. Br J Clin Pharma­col 1994; 37: 279–288.11. Manchanda SC, Krishnaswa­mi S. Combi­na­tion treatment with tri­me­ta­zi­di­ne and diltia­zem in stable angi­na pecto­ris. Heart 1997; 78: 353–357.

12. Le­vy S and Group of South of Fran­ce Investi­ga­tors. Combi­na­tion the­ra­py of tri­me­ta­zi­di­ne with diltia­zem in pa­tients with co­ro­na­ry arte­ry di­sea­se. Am J Cardiol 1995; 76(6): 12B–16B.

13. Mi­chae­li­des PA, Spi­ro­pou­los K, Di­mo­pou­los K et al. Antiangi­nal effi­ca­cy of the combi­na­tion of tri­me­ta­zi­di­ne–propra­no­lol compa­red with mo­no­sorbi­de di­nitra­te–propra­no­lol in pa­tients with stable angi­na. Clin Drug Invest 1997; 13: 8–14.

14. Szwed H, Sa­dowski Z, Eli­kowski W et al. Combi­na­tion treatment in stable effort angi­na using tri­me­ta­zi­di­ne and me­topro­lol. Re­sults of rando­mi­zed, double–blind, multi­centre stu­dy (TRIMPOL II). Eur Hear J 2001; 22: 2267–2274.

15. Hra­dec J, Fi­li­po­vá J. TRI­KET I a II (TRI­me­ta­zi­din v Kom­bi­na­ci s Exis­tu­jí­cí Te­ra­pií) – Vý­sled­ky čes­ké a slo­ven­ské multi­centrické stu­die u 320 ne­moc­ných se sta­bil­ní ná­ma­ho­vou angi­nou pecto­ris. Cor Va­sa 2001; 43: 436–442.

16. Kolbel F, Ba­daV. Tri­me­ta­zi­di­ne in ge­riatric pa­tients with stable angi­na pecto­ris: The Ti­ger Stu­dy. Int J Clin Pract 2003; 57: 867–870.

17. Vi­ta­le C, Wajnga­ten M, Spo­sa­to B et al. Tri­me­ta­zi­di­ne impro­ves left ventri­cu­lar function and quali­ty of li­ve in elderly pa­tients with co­ro­na­ry arte­ry di­sea­se. Eur Heart J 2004; 25: 1814–1821.

18. Lu C, Dabrowski P, Fra­gasso G et al. Effects of tri­me­ta­zi­di­ne on ische­mic left ventri­cu­lar dysfunction in pa­tients with co­ro­na­ry arte­ry di­sea­se. Am J Cardiol 1998; 82: 898–901.

19. Fra­gasso G, Piatti PM, Monti L et al. Short– and long–term be­ne­fi­cial effects of tri­me­ta­zi­di­ne in pa­tients with dia­be­tes and ische­mic cardio­myo­pathy. Am Heart J 2003; 146: 18–25.

20. Sellier P, Broustet JP. Assessment of anti–ische­mic and antiangi­nal effect at trough plasma concentra­tion and sa­fe­ty of tri­me­ta­zi­di­ne MR 35mg in pa­tients with stable angi­na pecto­ris. Am J Cardio­vasc Drugs 2003; 3: 361–369.

21. Ma­kolkin VI, Osadchiy K. Tri­me­ta­zi­di­ne mo­di­fied re­lea­se in the treatment of stable angi­na. Clin Drug Invest 2004; 24: 731–738.

22. Be­lardi­nelli R, Purca­ro A. Effects of tri­me­ta­zi­di­ne on the contracti­le response of chro­ni­cally dysfunctio­nal myocardium to low–do­se do­bu­ta­mi­ne in ische­mic cardio­myo­pathy. Eur Heart J 2001; 23: 2164–2170.

23. Chierchia SL. Tri­me­ta­zi­di­ne and left ventri­cu­lar ischae­mic dysfunction: an overview of cli­ni­cal evi­den­ce. Eur Heart J 2001; 3(Suppl O): 16–20.

24. Fra­gasso G, Piatti PM, Monti L et al. Acu­te effects of he­pa­rin admi­nistra­tion on the ische­mic threshold of pa­tients with co­ro­na­ry arte­ry di­sea­se: eva­lua­tion of the pro­tecti­ve ro­le of the me­ta­bo­lic mo­du­la­tor tri­me­ta­zi­di­ne. J Am Coll Cardiol 2002; 39: 413–419.

25. Tü­ne­rir B, Co­lak Ö, Ala­tas Ö et al. Measu­re­ment of tro­po­nin T to de­tect cardiopro­tecti­ve effect of tri­me­ta­zi­di­ne du­ring co­ro­na­ry arte­ry by­pass grafting. Ann Tho­rac Surg 1999; 68: 2173–2176.

26. Po­lonski L, Dec I, Wojnar R et al. Tri­me­ta­zi­di­ne li­mits the effects of myocardial ischae­mia du­ring percu­ta­neous co­ro­na­ry angioplasty. Curr Med Res Opin 2002; 18(7): 389–396.

27. Haffner SM, Lehto S, Ronne­maa T et al. Morta­li­ty from co­ro­na­ry heart di­sea­se in subjects with ty­pe 2 dia­be­tes and in nondia­be­tic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339(4): 229–234.

28. Coutinho M, Gerstein HC, Wang Y et al. The re­la­tionship between glu­co­se and in­ci­dent cardio­vascu­lar events: a me­ta­regression ana­ly­sis of published da­ta from 20 stu­dies of 95 783 indi­vi­duals follo­wed for 12.4 years. Dia­be­tes Ca­re 1999; 22(2): 233–240.

29. Bartnik M, Ry­dén L, Ferra­ri R et al. The pre­va­lence of abnormal glu­co­se re­gu­la­tion in pa­tients with co­ro­na­ry arte­ry di­sea­se across Euro­pe. The Euro Heart Survey on dia­be­tes and the heart. Eur Heart J 2004; 25(21): 1880–1890.

30. Pyora­la K, Lehto S, De Bacquer D et al (On be­half of the EUROASPI­RE I and II Groups). Risk factor ma­na­ge­ment in diabe­tic and non–diabe­tic pa­tients with co­ro­na­ry heart di­sea­se. Findings from the EUROASPI­RE I and II surveys. Diabe­to­lo­gia 2004; 47(7): 1257–1265.

31. Hasdai D, Be­har S, Wallentin L et al. A prospecti­ve survey of the cha­racte­ristics, treatments and outco­mes of pa­tients with acu­te co­ro­na­ry syndro­mes in Euro­pe and the Me­di­terra­nean ba­sin; The Euro Heart Survey of Acu­te Co­ro­na­ry Syndro­mes. Eur Heart J 2002; 23(15): 1190–1201.

32. Szwed H, Sa­dowski Z, Pa­chocki R et al. The antiische­mic effects and to­le­ra­bi­li­ty of tri­me­ta­zi­di­ne in co­ro­na­ry diabe­tic pa­tients. A substu­dy from TRIMPOL–1. Cardio­vasc Drugs Ther 1999; 13(3): 217–222.

33. Ro­sa­no GMC, Vi­ta­le C, Spo­sa­to B et al. Tri­me­ta­zi­di­ne impro­ves left ventri­cu­lar function in diabe­tic pa­tients with co­ro­na­ry arte­ry di­sea­se: a double–blind pla­ce­bo–controlled stu­dy. Cardio­vasc Diabe­tol 2003; 2(1): 16–25.

Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#